Northwest Biotherapeutics
Development-stage American pharmaceutical company
NWBO OTC Markets Group
SEC CIK 1072379 LEI 5493002DRWWEOWTT8005
Follow Northwest Biotherapeutics
Weekly email: filings, results
Revenue, last quarter
$883K
+341.5% vs same quarter last year
Net income
−$28.8M
−7.2% vs same quarter last year
EPS, diluted
−$0.02
+0% vs same quarter last year
Operating cash flow
−$8.8M
+37% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.4M | −$60.2M |
| FY24 | $1.4M | −$83.8M |
| FY23 | $1.9M | −$62.6M |
| FY22 | $1.7M | −$105M |
| FY21 | $1M | - |
| FY20 | $1.3M | −$529.8M |
| FY19 | $2.4M | −$20.8M |
| FY18 | $412K | −$35.8M |
| FY17 | $336K | −$73.1M |
| FY16 | $623K | −$80.2M |
| FY15 | $1.7M | −$114.7M |
| FY14 | $1.5M | −$135.6M |
| FY13 | $809K | −$65.8M |
| FY12 | $772K | −$67.3M |
| FY11 | $10K | −$32.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −4347.9% | −4365.9% |
| FY24 | - | −4812.4% | −6062.1% |
| FY23 | - | −2873.1% | −3240.1% |
| FY22 | - | −3991.7% | −6240.8% |
| FY21 | - | −5244% | - |
| FY20 | - | −6708.4% | −41039.6% |
| FY19 | - | −1161% | −863.6% |
| FY18 | - | −10068.2% | −8687.9% |
| FY17 | - | −16273.2% | −21768.8% |
| FY16 | - | −12723.3% | −12875.4% |
| FY15 | - | −7261.9% | −6598.1% |
| FY14 | - | −6956.2% | −9328.3% |
| FY13 | 100% | −6857.1% | −8132.1% |
| FY12 | 100% | −5676.8% | −8720.2% |
| FY11 | 100% | −267870% | −328300% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$46.3M |
| FY24 | −$58M |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | −$32M |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | −$37.8M |
| FY12 | −$22.8M |
| FY11 | −$14.8M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | $0 |
| FY14 | $0 |
| FY13 | $240K |
| FY12 | - |
| FY11 | - |
- Northwest Biotherapeutics
- Healthcare median
Show the numbers
| Year | Northwest Biotherapeutics | Healthcare median |
|---|---|---|
| FY25 | −4365.9% | −30.6% |
| FY24 | −6062.1% | −47% |
| FY23 | −3240.1% | −58% |
| FY22 | −6240.8% | −80.4% |
| FY21 | - | −71.9% |
| FY20 | −41039.6% | −62.2% |
| FY19 | −863.6% | −46.3% |
| FY18 | −8687.9% | −49.6% |
| FY17 | −21768.8% | −45.9% |
| FY16 | −12875.4% | −36% |
| FY15 | −6598.1% | −38.4% |
| FY14 | −9328.3% | −35.5% |
| FY13 | −8132.1% | −37.1% |
| FY12 | −8720.2% | −29.1% |
| FY11 | −328300% | −27.9% |